Literature DB >> 18023599

Efficacy of azithromycin in preventing pulmonary abscesses in foals.

Monica Venner1, Birte Reinhold, Martin Beyerbach, Karsten Feige.   

Abstract

The prophylactic application of azithromycin to prevent pulmonary abscesses in foals was evaluated on a stud with endemic Rhodococcus equi pneumonia. Forty-five foals served as untreated controls in two groups. Twenty-five foals were given azithromycin (10mg/kg) orally once daily for 4 weeks. The foals were examined once a week from birth to the age of 5 months. If clinical signs or leucocytosis were noted and pulmonary sonographic findings (diameter >10 mm) were observed, the diagnosis of abscessing pneumonia was made. The prevalence of pulmonary abscesses was similar in the control groups (31/45 foals), and in the azithromycin group (15/25 foals), but the foals in the azithromycin group were affected significantly later (median: day 83, range 67-123 days) (control groups: day 54, range 52-82; and 46, range 28-86 days). It was concluded that the application of azithromycin for 28 days post-natally does not reduce the prevalence of pulmonary abscesses in foals on a stud with endemic pneumonia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18023599     DOI: 10.1016/j.tvjl.2007.10.002

Source DB:  PubMed          Journal:  Vet J        ISSN: 1090-0233            Impact factor:   2.688


  8 in total

1.  Emergence of Resistance to Macrolides and Rifampin in Clinical Isolates of Rhodococcus equi from Foals in Central Kentucky, 1995 to 2017.

Authors:  Laura Huber; Steeve Giguère; Nathan M Slovis; Craig N Carter; Bonnie S Barr; Noah D Cohen; Justine Elam; Erdal Erol; Stephan J Locke; Erica D Phillips; Jacqueline L Smith
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

2.  Efficacy of gamithromycin for the treatment of foals with mild to moderate bronchopneumonia.

Authors:  F Hildebrand; M Venner; S Giguère
Journal:  J Vet Intern Med       Date:  2015-01       Impact factor: 3.333

3.  TRPM2 SNP genotype previously associated with susceptibility to Rhodococcus equi pneumonia in Quarter Horse foals displays differential gene expression identified using RNA-Seq.

Authors:  Cole M McQueen; Canaan M Whitfield-Cargile; Kranti Konganti; Glenn P Blodgett; Scott V Dindot; Noah D Cohen
Journal:  BMC Genomics       Date:  2016-12-05       Impact factor: 3.969

4.  Efficacy of Tulathromycin for the Treatment of Foals with Mild to Moderate Bronchopneumonia.

Authors:  D Rutenberg; M Venner; S Giguère
Journal:  J Vet Intern Med       Date:  2017-04-19       Impact factor: 3.333

5.  Randomized, controlled trial comparing Rhodococcus equi and poly-N-acetyl glucosamine hyperimmune plasma to prevent R equi pneumonia in foals.

Authors:  Susanne K Kahn; Colette Cywes-Bentley; Glenn P Blodgett; Nathan M Canaday; Carly E Turner-Garcia; Patricia Flores-Ahlschwede; Laurie L Metcalfe; Mark Nevill; Mariana Vinacur; Patrick J Sutter; Sarah C Meyer; Angela I Bordin; Gerald B Pier; Noah D Cohen
Journal:  J Vet Intern Med       Date:  2021-11-05       Impact factor: 3.333

Review 6.  Genetic Susceptibility to Rhodococcus equi.

Authors:  C M McQueen; S V Dindot; M J Foster; N D Cohen
Journal:  J Vet Intern Med       Date:  2015-09-04       Impact factor: 3.333

7.  The opportunistic intracellular bacterial pathogen Rhodococcus equi elicits type I interferon by engaging cytosolic DNA sensing in macrophages.

Authors:  Krystal J Vail; Bibiana Petri da Silveira; Samantha L Bell; Noah D Cohen; Angela I Bordin; Kristin L Patrick; Robert O Watson
Journal:  PLoS Pathog       Date:  2021-09-02       Impact factor: 6.823

8.  Serum Antibody Activity against Poly-N-Acetyl Glucosamine (PNAG), but Not PNAG Vaccination Status, Is Associated with Protecting Newborn Foals against Intrabronchial Infection with Rhodococcus equi.

Authors:  Noah D Cohen; Susanne K Kahn; Colette Cywes-Bentley; Sophia Ramirez-Cortez; Amanda E Schuckert; Mariana Vinacur; Angela I Bordin; Gerald B Pier
Journal:  Microbiol Spectr       Date:  2021-07-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.